Twenty Four Month Extension Study of BA058-05-003



Status:Completed
Conditions:Osteoporosis, Postmenopausal Syndrome
Therapuetic Areas:Endocrinology, Rheumatology
Healthy:No
Age Range:Any
Updated:4/14/2017
Start Date:October 2012
End Date:October 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

The purpose of this study is to provide 24 months of standard of care data on subjects
previously enrolled in study BA058-05-003.


Inclusion Criteria:

1. The subject was enrolled, randomized to either the BA058 (abaloparatide) or placebo
arm, and successfully completed Study BA058-05-003.

Exclusion Criteria:

1. Were withdrawn from Study BA058-05-003 for any reason.

2. Experienced a treatment-related SAE during Study BA058-05-003.
We found this trial at
5
sites
Clinical Trial Facility in Atlanta Georgia
Atlanta, Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Trial Facility in Bethesda Maryland
Bethesda, Maryland
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical Trial Facility in Buenos Aires
Buenos Aires,
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
Clinical Trial Facility in Lakewood Colorado
Lakewood, Colorado 80228
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
Clinical Trial Facility in NMiami Florida
NMiami, Florida
?
mi
from
NMiami, FL
Click here to add this to my saved trials